Prime Medicine (PRME) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free PRME Stock Alerts $7.16 +0.08 (+1.13%) (As of 08:16 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 8:43 AM | marketbeat.comHC Wainwright Begins Coverage on Prime Medicine (NYSE:PRME)HC Wainwright assumed coverage on shares of Prime Medicine in a research note on Monday. They issued a "buy" rating and a $10.00 target price for the company.May 18 at 4:16 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Stock Rating Upgraded by CitigroupMay 17 at 9:00 PM | marketbeat.comNikko Asset Management Americas Inc. Sells 115,819 Shares of Prime Medicine, Inc. (NYSE:PRME)Nikko Asset Management Americas Inc. cut its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,519,029 shares of the coMay 17 at 12:50 PM | msn.comCitigroup Upgrades Prime Medicine (PRME)May 17 at 6:27 AM | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 17 at 6:15 AM | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 16, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 4.1%Prime Medicine (NYSE:PRME) Shares Up 4.1%May 16, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Upgraded at CitigroupCitigroup upgraded shares of Prime Medicine from a "neutral" rating to a "buy" rating and set a $10.00 target price on the stock in a report on Thursday.May 15, 2024 | msn.comWhat is Prime Day, exactly? How Amazon's giant deals day worksMay 15, 2024 | americanbankingnews.comPrime Medicine (NYSE:PRME) Lifted to "Sell" at StockNews.comMay 15, 2024 | americanbankingnews.comPrime Medicine (NYSE:PRME) Price Target Cut to $15.00May 15, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Upgraded to Sell by StockNews.comStockNews.com upgraded shares of Prime Medicine to a "sell" rating in a report on Tuesday.May 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on FDA Trial Approval and Strong FinancialsMay 13, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up to $5.61Prime Medicine (NYSE:PRME) Shares Gap Up to $5.61May 13, 2024 | marketbeat.comJPMorgan Chase & Co. Trims Prime Medicine (NYSE:PRME) Target Price to $15.00JPMorgan Chase & Co. decreased their price target on Prime Medicine from $16.00 to $15.00 and set an "overweight" rating for the company in a report on Monday.May 13, 2024 | globenewswire.comPrime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQMay 10, 2024 | finanznachrichten.dePrime Medicine, Inc.: Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Robust Preclinical Data and Prime Editing Technology ProspectsMay 10, 2024 | investorplace.comPRME Stock Earnings: Prime Medicine Beats EPS for Q1 2024May 10, 2024 | msn.comPrime Medicine GAAP EPS of -$0.44 beats by $0.03, revenue of $0.59M misses by $0.32MMay 10, 2024 | globenewswire.comPrime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 8, 2024 | globenewswire.comPrime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)May 7, 2024 | marketbeat.comPrime Medicine's (PRME) "Buy" Rating Reiterated at Jefferies Financial GroupJefferies Financial Group restated a "buy" rating and set a $15.00 price objective (down previously from $23.00) on shares of Prime Medicine in a report on Tuesday.May 6, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 2.5%Prime Medicine (NYSE:PRME) Stock Price Down 2.5%May 6, 2024 | marketbeat.com144,288 Shares in Prime Medicine, Inc. (NYSE:PRME) Bought by Vestmark Advisory Solutions Inc.Vestmark Advisory Solutions Inc. acquired a new stake in Prime Medicine, Inc. (NYSE:PRME - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 144,288 shares of the company's stock, valued at approximately $1,278,May 1, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 5.7%Prime Medicine (NYSE:PRME) Trading 5.7% HigherApril 29, 2024 | msn.comFDA clears Prime Medicine to begin gene therapy clinical testingApril 29, 2024 | marketwatch.comPrime Medicine Shares Rise 13% After FDA Clears IND ApplicationApril 29, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up to $4.43Prime Medicine (NYSE:PRME) Shares Gap Up to $4.43April 29, 2024 | marketwatch.comPrime Medicine Gets FDA Clearance for PM359 IND ApplicationApril 29, 2024 | markets.businessinsider.comPrime Medicine Announces FDA Clearance Of IND Application For Pm359 - Quick FactsApril 29, 2024 | globenewswire.comPrime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)April 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical OutlookApril 25, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Reaches New 12-Month Low at $4.32Prime Medicine (NYSE:PRME) Hits New 1-Year Low at $4.32April 23, 2024 | marketbeat.comPrime Medicine's (PRME) "Outperform" Rating Reiterated at WedbushWedbush restated an "outperform" rating and set a $12.00 price objective on shares of Prime Medicine in a research note on Tuesday.April 23, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 8.8%Prime Medicine (NYSE:PRME) Stock Price Up 8.8%April 23, 2024 | globenewswire.comPrime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsApril 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic ProgressApril 22, 2024 | nasdaq.comChardan Capital Initiates Coverage of Prime Medicine (PRME) with Buy RecommendationApril 22, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up to $4.51Prime Medicine (NYSE:PRME) Shares Gap Up to $4.51April 22, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Research Coverage Started at Chardan CapitalChardan Capital assumed coverage on shares of Prime Medicine in a report on Monday. They set a "buy" rating and a $17.00 price objective for the company.April 18, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 5.7%Prime Medicine (NYSE:PRME) Trading Down 5.7%April 15, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Sets New 12-Month Low at $5.46Prime Medicine (NYSE:PRME) Sets New 12-Month Low at $5.46April 11, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Trading Down 4.1%Prime Medicine (NYSE:PRME) Trading Down 4.1%April 11, 2024 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Stock Position Boosted by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in Prime Medicine, Inc. (NYSE:PRME - Free Report) by 18.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,951,793 shares of the company's stock after acquiring an additional 617,310April 10, 2024 | uk.investing.comTD Cowen initiates Prime Medicine stock with Buy on editing platformApril 8, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Up 5.4%Prime Medicine (NYSE:PRME) Trading 5.4% HigherApril 8, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Now Covered by Analysts at TD CowenTD Cowen started coverage on Prime Medicine in a research report on Monday. They set a "buy" rating on the stock.April 5, 2024 | marketbeat.comPrime Medicine (NYSE:PRME) Sets New 52-Week Low at $5.48Prime Medicine (NYSE:PRME) Reaches New 12-Month Low at $5.48April 5, 2024 | marketbeat.comPrime Medicine, Inc. to Post Q1 2024 Earnings of ($0.45) Per Share, Wedbush Forecasts (NYSE:PRME)Prime Medicine, Inc. (NYSE:PRME - Free Report) - Research analysts at Wedbush issued their Q1 2024 earnings per share estimates for Prime Medicine in a report issued on Tuesday, April 2nd. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.45) for the Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Does this make you sick? (Ad)The US Dollar Is "Finished" A deteriorating economy, global instability, and a weakened banking system have pushed the U.S. financial system to the brink, imperiling the value of your savings and investments. Get your Free Wealth Protection Kit PRME Media Mentions By Week PRME Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRME News Sentiment▼0.550.42▲Average Medical News Sentiment PRME News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRME Articles This Week▼182▲PRME Articles Average Week Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CARGO Therapeutics News REGENXBIO News Mesoblast News ProKidney News Relay Therapeutics News HilleVax News Humacyte News Kyverna Therapeutics News iTeos Therapeutics News Immatics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:PRME) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
